The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments. 

Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.

BGI is currently awaiting final approval for the offering from the China Securities Regulatory Commission.

A study focused on rare CNVs unearthed a subset of Tourette cases affected by deletions in the NRXN1 gene or duplications in the CNTN6 gene. 

Euroimmun is a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing, according to PerkinElmer.

The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.

DuPont Pioneer has acquired the exclusive rights to ERS Genomics' portfolio of CRISPR-Cas genome-editing technologies for all plant and agricultural applications.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.